|
English
|
正體中文
|
简体中文
|
全文筆數/總筆數 : 80990/80990 (100%)
造訪人次 : 41077590
線上人數 : 948
|
|
|
資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.lib.ncu.edu.tw/handle/987654321/92047
|
題名: | 以溫和水相法封裝胰島素至鋁基底金屬有機骨架材料A520於糖尿病治療之研究;A Mild Water-based Approach for Obtaining Encapsulation of Insulin into Aluminum -based Metal-Organic Frameworks A520 for Diabetic Treatments |
作者: | 曾昭瑋;Tzeng, Jau-Wei |
貢獻者: | 化學學系 |
關鍵詞: | 鋁基底有機金屬骨架材料;胰島素;蛋白固定化;糖尿病治療;溫和水相合成法 |
日期: | 2023-08-14 |
上傳時間: | 2024-09-19 14:48:11 (UTC+8) |
出版者: | 國立中央大學 |
摘要: | 糖尿病為一種常見的慢性代謝異常疾病,根據統計全球現有五億人罹患糖尿病。即使目前有設計許多治療方法來治療第一型與第二型糖尿病,但較為嚴重的糖尿病患者只能透過直接注射胰島素來治療,所以開發口服胰島素來減輕患者因注射所帶來的痛苦與不便是必要的。 有機金屬骨架材料 (MOFs) 是一種新興的奈米孔洞材料,其孔洞性質在各領域皆有很大的發展潛力,也是酵素固定化與藥物載體理想的材料之一。 本篇論文成功的以較溫和的水相環境快速合成鋁基底金屬骨架有機材料A520,其材料擁有耐酸的性質,並且其中心金屬為鋁,在醫學上鋁鹽已被用作佐劑已有很長的歷史,對人體有相當好的生物相容性,而有機配體反丁烯二酸皆對於人體有很低的毒性,因此A520具有很大的潛力能夠成為口服胰島素藥物載體。本篇論文也成功的以鋁基底金屬有機骨架材料包覆胰島素,其包覆率約為5%。此外,本論文也使用模擬腸液、胃液與血液的溶液來測試材料的穩定度,其結果也驗證了材料對於胃與小腸環境之耐受性與在血液之環境能夠崩解之特性。 本論文亦成功以同樣的方式合成CAT@A520,並且在大分子蛋白水解酶(proteinase K)的作用下,能夠保護過氧化氫酶並維持良好的催化活性。其證明此材料具有一定的孔洞篩選性,能夠保護酵素不被大分子蛋白酶所分解而失活,而同理可以推論其可以保護胰島素不被胃中大分子的胃蛋白酶所攻擊而分解。本研究充分顯示了A520對於成為胰島素藥物載體的可行性,期望其能夠對於口服胰島素的發展帶來突破。;Diabetes is a common chronic metabolic disorder. According to statistics, there are currently 500 million people worldwide suffering from diabetes. Despite the availability of various treatment methods for type 1 and type 2 diabetes, individuals with severe diabetes can only rely on direct insulin injections for treatment. Therefore, the development of oral insulin (INS) administration to alleviate the pain and inconvenience caused by injections is necessary.Metal-organic frameworks (MOFs) are promising porous nanoscale materials with diverse applications in various fields. One area where they show great potential is in enzyme immobilization and drug delivery systems. This paper successfully achieved the rapid synthesis of aluminum-based metal-organic framework material A520 in a relatively mild water-based environment. The material exhibits acid-resistant properties, with aluminum as the central metal. Aluminum salts have a long history of use as adjuvants in medicine and are known for their good biocompatibility with the human body. Additionally, the organic ligand, fumaric acid, has low toxicity to the human body. Therefore, A520 has great potential to serve as an oral insulin drug carrier. The study achieved a 5% insulin loading capacity in the INS@A520 biocomposite. A520 exhibited remarkable stability in simulated gastric and intestinal fluids, as well as efficient dissolution in the bloodstream. This highlights its potential as an innovative carrier for oral insulin delivery, paving the way for future advancements in MOF-based drug delivery systems. Using a similar approach, we successfully obtained the CAT@A520 biocomposite by encapsulating the Catalase (CAT) enzyme within A520. In the presence of the proteinase K enzyme, this material effectively shields CAT, maintaining its catalytic activity. This showcases the material′s selective pore behavior, safeguarding enzymes from degradation by large molecule proteases and preserving their functionality. Consequently, it can be inferred that A520 may also shield insulin from gastric proteases′ attack and degradation in the stomach. This research strongly supports the viability of A520 as an insulin drug carrier, holding the potential for significant advancements in oral insulin development. |
顯示於類別: | [化學研究所] 博碩士論文
|
文件中的檔案:
檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
index.html | | 0Kb | HTML | 11 | 檢視/開啟 |
|
在NCUIR中所有的資料項目都受到原著作權保護.
|
::: Copyright National Central University. | 國立中央大學圖書館版權所有 | 收藏本站 | 設為首頁 | 最佳瀏覽畫面: 1024*768 | 建站日期:8-24-2009 :::